Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Modelling targeted therapy efficacy in NRAS mutant conjunctival melanoma.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Sept 2026

Välimäki Eetu, Alanne Erika, Suhonen Janne, Ruiz Wilder, Torkkila Jori, Kukkula Antti, Hartiala Pauliina, Vainio Paula, Sundvall Maria, Rantala Juha K

Abstract excerpt

Conjunctival melanoma (CoM) is an ultra-rare ocular melanoma that originates from transformed melanocytes of the conjunctiva. CoM shares a common embryonic cell of origin as cutaneous melanoma and manifests as highly aggressive malignancy. Despite cellular similarity of conjunctival and cutaneous melanoma, the pathogenesis, genetic landscape, response to treatment, and prognosis of these malignancies differ...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Conjunctival Neoplasms

Share to GTP Phosphohydrolases

Share to Melanoma

Share to Membrane Proteins

Share to Molecular Targeted Therapy

Share to Treatment Outcome

Source

Identifiers

PMID: 42537395
DOI: 10.1016/j.biopha.2026.119803

Genes

NRAS
TERT
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Modelling targeted therapy efficacy in NRAS mutant conjunctival melanoma.PMID 42537395Read ↗

NRAS mutant melanoma: Towards better therapies.Semantic proximity Read ↗

Conjunctival Melanoma: Current Treatments and Future Options.Semantic proximity Read ↗

High-throughput drug screening in advanced pre-clinical 3D melanoma models identifies potential first-line therapies for NRAS-mutated melanomaSemantic proximity Read ↗

Overview of disease pathology and discussion advancements in immunotherapy for the treatment of uveal melanomaSemantic proximity Read ↗

Immunotherapy in Melanoma: A Dynamic Frontier in Cancer Treatment : Author List.Semantic proximity Read ↗

A mutation-resolved therapeutic atlas of NRAS-mutant melanoma reveals genotype-selective response to RAS(ON) inhibition and adaptive STAT3 survivalSemantic proximity Read ↗

Targeting mutant NRAS signaling pathways in melanoma.Semantic proximity Read ↗

Uveal melanoma: From diagnosis to treatment and the science in between.Semantic proximity Read ↗

Novel treatment strategy for NRAS-mutated melanoma through a selective inhibitor of CD147/VEGFR-2 interaction.Semantic proximity Read ↗

Advances in Understanding Drug Resistance Mechanisms and Innovative Clinical Treatments for Melanoma.Semantic proximity Read ↗

Development of Personalized Strategies for Precisely Battling Malignant Melanoma.Semantic proximity Read ↗

New strategies in metastatic melanoma: oncogene-defined taxonomy leads to therapeutic advances.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.